Compare Ingersoll Rand (IR) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs Repligen Corporation Common Stock — how do they compare? Ingersoll Rand trades at $77.95 (market cap $30.24B), while Repligen Corporation Common Stock trades at $178.2 (market cap $11.31B). The key difference: Ingersoll Rand is far larger — about 2.7× Repligen Corporation Common Stock's market cap, and Ingersoll Rand pays a 0.1% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 9 Days and Repligen Corporation Common Stock for 0 Days on average.
| IR | RGEN | |
|---|---|---|
Market Cap | $30.24B | $11.31B |
Volume | 2,589,571 | 1,216,919 |
Sector | Industrials | Health |
52-Week High | $98.76 | $194.57 |
52-Week Low | $68.54 | $102.87 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $33.90B | $11.20B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ingersoll Rand (IR) trades at $78.95, down 0.18% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $0.86 versus $0.827 expected, marking three consecutive quarterly beats. Revenue guidance was raised to 4.5%-6.5% for 2026, with improving demand across business cycles. Analyst consensus is bullish with a $90.60 price target, representing 15% upside potential from current levels.
The outlook remains positive with accelerating long-cycle orders and strategic acquisitions expanding capabilities. Key risks include margin compression and elevated P/E ratio of 32.62. Institutional ownership increased with HSBC boosting its position by 12.9% in Q2 2026. The stock offers growth potential but requires monitoring of profitability trends and valuation sustainability.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
